zoledronic acid has been researched along with Bone Loss, Osteoclastic in 259 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (3.47) | 18.2507 |
| 2000's | 120 (46.33) | 29.6817 |
| 2010's | 107 (41.31) | 24.3611 |
| 2020's | 23 (8.88) | 2.80 |
| Authors | Studies |
|---|---|
| Martin, MB; Oldfield, E; Szabo, CM | 1 |
| Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L | 1 |
| Kotsikorou, E; Oldfield, E | 1 |
| Chan, JM; Flessner, R; Gómez, AO; González-Pacanowska, D; Jennings, S; Kosztowski, T; Kotsikorou, E; Meints, GA; Morita, CT; Odeh, S; Oldfield, E; Papapoulos, SE; Raker, AM; Sanders, JM; Schwerdtfeger, C; Song, Y; van Beek, ER; Wang, H; Zhang, Y | 1 |
| Blangy, A; Cherfils, J; Ferrandez, Y; Gilardone, M; Morel, A; Morko, J; Mounier, L; Roche, D; Vääräniemi, J | 1 |
| Cheng, YT; Huang, XL; Li, JP; Liao, J; Liu, C; Shi, XM; Zhou, Q | 1 |
| Azetsu, Y; Chatani, M; Ikeda, M; Karakawa, A; Sakai, N; Suzuki, N; Takami, M; Takizawa, H | 1 |
| Arana-Chavez, VE; Bradaschia-Correa, V; de Faria, LP; Rezende-Teixeira, P; Ribeiro-Santos, GC | 1 |
| Ding, D; Feng, G; Jin, Q; Ma, L; Pei, X; Wang, L; Yan, J; Yang, Y; Zhou, Y | 1 |
| Aoki, K; Nakamura, M; Saito, N; Ueda, K; Yamamoto, Y; Yudasaka, M; Zhang, M | 1 |
| Horne, AM; Jabr, A; Liu, M; Mellar, A; Reid, IR; Wen, J | 1 |
| Teles, AR; Zafeiris, CP; Zafeiris, ΕP; Zogakis, PN | 1 |
| Harsløf, T; Jørgensen, NR; Langdahl, B; Sølling, AS | 1 |
| Cai, X; Chai, Z; Chen, J; Dou, R; Du, C; Hu, Y; Jia, F; Liu, X; Liu, Y; Ruan, L; Zhang, J; Zhang, X | 1 |
| Chen, B; Chen, F; Chen, J; Chen, X; Feng, Z; Huang, B; Kong, X; Li, J; Song, H; Tao, S; Wei, X; Yao, Q; You, T; Yu, H; Zhang, X; Zhao, F; Zheng, L; Zheng, Z | 1 |
| Arnett, TR; Davies, BK; Hibbert, AP; Holdsworth, G; Orriss, IR; Roberts, HC; Roberts, SJ; Tickner, JC | 1 |
| Chen, HL; Hu, JP; Lan, L; Li, JF; Li, Q | 1 |
| Anastasilakis, AD; Appelman-Dijkstra, NM; Makras, P; Papapoulos, SE; Polyzos, SA | 1 |
| Kushima, C; Nakazato, M; Uchida, T; Yamaguchi, H; Yonekawa, T | 1 |
| Kumar, A; Qayoom, I; Teotia, AK | 1 |
| Ando, Y; Arai, E; Hase, T; Ikuta, K; Ishiguro, N; Kikumori, T; Maeda, O; Mitsuma, A; Nishida, Y; Shimokata, T; Sugishita, M; Urakawa, H | 1 |
| Hu, JB; Lu, CB; Sang, HX; Wang, FQ; Yang, XJ; Yang, Z; Zhang, Y; Zou, JW | 1 |
| Bianchi, G; Camellino, D; Girasole, G; Giusti, A; Iervasi, E; Papapoulos, SE; Saverino, D | 1 |
| Dong, W; Gu, Y; Jia, S; Liang, Y; Lin, Y; Qi, M; Zuo, G | 1 |
| Oryan, A; Sahvieh, S | 1 |
| Kasai, H; Mori, Y; Ose, A; Shiraki, M; Tanigawara, Y | 1 |
| da Silva Martins, C; Dantas, HV; de Carvalho Leitão, RF; de Castro Brito, GA; de Sousa Ferreira, VC; de Sousa, FB; de Sousa, FRN; Girão-Carmona, VCC; Goes, P | 1 |
| Cheng, YT; Hong, W; Huo, H; Liao, DJ; Liao, J; Ma, H; Tang, ZL; Zellmer, L; Zhou, Q | 1 |
| Liel, Y; Plakht, Y; Tailakh, MA | 1 |
| Allen, MR; Alvarez, MB; Bidwell, JP; Burr, DB; Childress, P; Condon, KW; Davis, H; He, Y; Hernandez-Buquer, S; Plotkin, LI; Robling, AG; Shao, Y; Stayrook, KR; Warden, SJ; Wek, RC; Yang, FC | 1 |
| Antoniali, C; de Campos, N; Ervolino, E; Fucini, SE; Furlaneto, FAC; Messora, MR; Nagata, MJH; Pola, NM; Santinoni, CS | 1 |
| Lüftner, D; Niepel, D; Steger, GG | 1 |
| Dai, K; Hao, Y; Li, G; Pei, J; Wang, L; Yuan, G; Zhang, L | 1 |
| Baas, J; Jakobsen, T; Kold, S; Rahbek, O; Shiguetomi-Medina, J; Soballe, K | 1 |
| Dezawa, A; Kamijo, R; Karakawa, A; Miyamoto, A; Nakamura, S; Shibuya, I; Takami, M | 1 |
| Ge, XY; Hao, KY; Jiang, X; Lin, Y; Ma, T; Zhang, BR; Zhang, Y | 1 |
| Aguirre, JI; Bhattacharyya, N; Castillo, EJ; Jiron, JM; Kimmel, DB; Mendieta Calle, JL; Messer, JG; Van Poznak, C | 1 |
| Ishiguro, M; Kasai, H; Mori, Y; Ose, A; Serada, M; Shiraki, M; Tanigawara, Y | 1 |
| Jia, N; Jin, X; Li, P; Shen, Y; Xu, D; Yang, H | 1 |
| Cheung, LC; Chua, GA; Foley, B; Ford, J; He, B; Howlett, M; Hughes, AM; Kees, UR; Kotecha, RS; Mullighan, CG; Oommen, J; Singh, S; Skut, P; Tickner, J; Wells, JE | 1 |
| Hadji, P; Hars, O; Kann, PH; Kyvernitakis, I; Thomasius, F | 1 |
| Charlesworth, G; Daroszewska, A; Prior, A; Ralston, SH; Rose, K; Rose, L; Sarsam, N; van 't Hof, RJ | 1 |
| Akpinar, F; Aktas, I; Bilgic, B; Bostan, AB; Illeez, OG; Ozkan, FU; Ozkan, K | 1 |
| Dong, W; Feng, X; Liu, H; Qi, M; Wang, Y | 1 |
| Gui, K; Ji, W; Jiang, Z; Liang, G; Ma, J; Xiong, M; Yu, W; Yuan, F; Zeng, X; Zhang, C; Zhang, F; Zhao, M | 1 |
| Alvarenga, JC; Araújo, MJCLN; Custódio, MR; David-Neto, E; Dos Reis, LM; Elias, RM; Graciolli, FG; Jorgetti, V; Marques, IDB; Moysés, RMA; Pereira, RMR | 1 |
| Geng, D; Guo, X; Liu, Y; Xu, Y; Yang, H; Zhou, W | 1 |
| Body, JJ; Costa, L; Gonzalez-Suarez, E; Niepel, D; Terpos, E; von Moos, R | 1 |
| Ebbinghaus, M; Eitner, A; Hess, A; Hilger, I; Kamradt, T; Müller, S; Schaible, HG; Segond von Banchet, G; Wank, I | 1 |
| Bonnet, N; Ferrari, S; Lesclous, P; Saffar, JL | 1 |
| Basile, G; Brancatelli, S; Catalano, A; Cucinotta, D; Lasco, A; Morabito, N | 1 |
| Carlton, MM; Dirksen, WP; Hildreth, BE; Lanigan, LG; London, CA; Martin, CK; Pillai, SP; Rosol, TJ; Simmons, JK; Toribio, RE; Werbeck, JL | 1 |
| Bolland, M; Gamble, G; Grey, A; Horne, A; Mihov, B; Reid, IR; Wong, S | 1 |
| Damron, TA; Keenawinna, L; Mann, KA; Oest, ME; Spadaro, J | 1 |
| Bredeson, CN; Burns, LJ; DeFor, TE; Hari, P; Vesole, DH | 1 |
| Anghel, R; Bachmann, A; Bekşac, M; Brodowicz, T; Finek, J; Komadina, R; Krzemieniecki, K; Lang, I; Marencak, J; Pecherstorfer, M; Rordorf, T; von Moos, R; Vrbanec, D; Zielinski, C | 1 |
| Bakhous, A; Waheed, S; Zhu, H | 1 |
| Abe, M; Kawazoe, K; Kujime, T; Minakuchi, K; Okada, N; Shinohara, Y; Teraoka, K | 1 |
| Catalfamo, L; Centofanti, A; Cutroneo, G; De Ponte, FS; Favaloro, A; Runci, M; Siniscalchi, EN | 1 |
| Baas, J; Barckman, J; Bechtold, JE; Søballe, K; Sørensen, M | 1 |
| Endo, Y; Kiyama, T; Kuroishi, T; Oizumi, T; Okada, S; Sasaki, K; Sato, E; Sugawara, S; Takahashi, T; Tanaka, Y | 1 |
| Debiais, F | 1 |
| Costa, L; Dansey, R; Feng, A; Henry, D; Hirsh, V; Hungria, V; Jun, S; Scagliotti, G; Smith, G; Vadhan-Raj, S; von Moos, R; Woll, PJ; Yeh, H | 1 |
| Barba-Recreo, P; Burgueño, M; Del Castillo Pardo de Vera, JL; García-Arranz, M; Yébenes, L | 1 |
| Crockett, JC; Das, S; Edwards, PA; Rogers, MJ | 1 |
| Bouxsein, ML; Brooks, DJ; Demay, MB; Louis, L; Zhu, ED | 1 |
| Aati, O; Chhana, A; Dalbeth, N; Doyle, AJ; Gamble, GD; Horne, A; House, ME; McQueen, FM; Reid, IR; Roger, M | 1 |
| Ando, T; Cates, JM; Cole, HA; Haro, H; Ohba, T; Schoenecker, JG; Schwartz, HS; Slosky, DA | 1 |
| Irwig, MS | 1 |
| Alves, A; Arnoldi, J; Procter, P | 1 |
| Guo, X; Lu, X; Ni, B; Shi, J; Xie, N; Zeng, Y; Zhu, M; Zhu, Y | 1 |
| Bobyn, J; Kathy, M; Little, DG; Rasch, A; Schindeler, A | 1 |
| Carson, K; Colditz, G; Gage, B; Luo, S; Sanfilippo, KM; Tomasson, M; Vij, R; Weilbaecher, K | 1 |
| Anderson, KC; Ghobrial, IM; Laubach, JP; Munshi, NC; Nemani, N; Patel, CG; Raje, NS; Richardson, PG; Santo, L; Schlossman, RL; Scullen, TA; Yee, AJ | 1 |
| Ding, S; Li, J; Li, P; Li, R; Qi, M; Xu, C | 1 |
| Croucher, PI; Eaton, CL; Fowles, CA; Holen, I; Meek, J; Ottewell, PD; Wang, N | 1 |
| Aghaloo, TL; Bezouglaia, O; Cheong, S; Cirelli, JA; de Molon, RS; Dry, SM; Pirih, F; Tetradis, S | 1 |
| Buckwalter, JA; Fredericks, DC; Malandra, AE; Morcuende, J; Odgren, PR; Otero, JE; Stevens, JW | 1 |
| Beck, JT; Bilic, S; Isaacs, R; Iyer, SP; Kelly, KR; Munshi, NC; Sen, S; Shah, J; Stewart, AK | 1 |
| Kang, MK; Kim, RH; Kim, T; Lee, C; Liu, H; Park, NH; Park, S; Shi, S; Shin, KH; Williams, DW; Wu, H; Yagita, H; Yang, P | 1 |
| Gao, AC; Ghosh, PM | 1 |
| Kettenberger, U; Pioletti, DP; Procter, P; Ston, J; Thein, E | 1 |
| Dong, W; Li, P; Lin, J; Qi, M; Sun, H; Zhang, P | 1 |
| Askmyr, M; Baker, EK; Ebeling, PR; Harrison, SJ; Jovic, T; Neeson, P; Purton, LE; Quach, JM; Ritchie, D; Walsh, NC | 1 |
| Criscitiello, C; Curigliano, G; De Laurentiis, M; De Placido, S; Esposito, A; Gelao, L; Goldhirsch, A; Santangelo, M; Viale, G | 1 |
| Hashimoto, A; Horiguchi, H; Ibata, S; Iyama, S; Kamihara, Y; Kato, J; Kobune, M; Ono, K; Sato, T; Takada, K; Takimoto, R; Tatekoshi, A | 1 |
| Chunfeng, X; Hong, S; Jueshan, L; Mengchun, Q; Wei, D; Xiaojie, F | 1 |
| Aghaloo, TL; Bezouglaia, O; Boyce, RW; de Molon, RS; Dry, SM; Dwyer, D; Kostenuik, P; Pirih, FQ; Shimamoto, H; Tetradis, S | 1 |
| Gomes Filho, JE; Kobayashi, J; Kobayashi, M; Matsuda, S; Ohba, S; Sano, K; Wayama, MT; Yoshida, H; Yoshimura, H | 1 |
| Jiao, K; Kumar, S; Li, JY; Messer, R; Niu, LN; Pashley, DH; Pei, DD; Pramanik, C; Tay, FR; Yuan, H | 1 |
| Brüel, A; Henriksen, K; Thomsen, JS; Vegger, JB; Wendelboe, MH | 1 |
| Jiang, Y; Li, M; Liu, Y; Lv, F; Ma, DD; Song, LJ; Wang, JW; Wang, JY; Wang, O; Xia, WB; Xing, XP; Xu, XJ | 1 |
| Nakamura, T; Shiraki, M; Suzuki, H; Tanaka, S; Ueda, S | 1 |
| Cheng, N; Ha, S; Hong, C; Kim, R; Kwon, T; Lee, D; Lim, R; Olson, J; Park, J; Tetradis, S; Ting, K; Zhang, X | 1 |
| Boyce, BF; Li, J; Li, X; Pei, L; Sun, W; Wang, M; Wang, Z; Xing, L; Zhang, H | 1 |
| Alon, US; Freundlich, M | 1 |
| Fukawa, T; Kamiya, S; Wada, S | 1 |
| Body, JJ | 3 |
| Greiner, S; Kadow-Romacker, A; Schmidmaier, G; Wildemann, B | 1 |
| Buijs, JT; Löwik, CW; Papapoulos, SE; Que, I; van der Pluijm, G | 1 |
| Cunnane, G; Delaney, H; Doran, MF; Sheane, BJ | 1 |
| Aki, SZ; Cetiner, M; Cetiner, S; Gultekin, SE; Haznedar, R; Kahraman, SA; Kocakahyaoglu, B; Sucak, GT | 1 |
| Cho, SK; Lee, FY; Seo, SW; Storer, SK | 1 |
| Asuncion, F; Chiusaroli, R; Khatri, R; Kostenuik, P; Ohishi, M; Ominsky, M; Schipani, E; Thomas, C | 1 |
| Amir, E; Clemons, MJ; Dranitsaris, G; Simmons, CE; Trinkaus, M | 1 |
| Coleman, RE; Winter, MC | 1 |
| Evdokiou, A; Findlay, DM; Hay, S; Labrinidis, A; Liapis, V | 1 |
| Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M | 1 |
| Bubbear, JS; Ferguson-Pell, M; Gall, A; Keen, RW; Middleton, FR; Swaminathan, R | 1 |
| Bundred, N; Coleman, R; Davidson, N; de Boer, R; Eidtmann, H; Llombart-Cussac, A; Miller, J; Neven, P; Schenk, N; von Minckwitz, G | 1 |
| Bolland, M; Gamble, G; Grey, A; Horne, A; Reid, IR; Wattie, D | 1 |
| Abildgaard, N; Delaisse, JM; Lund, T; Plesner, T | 1 |
| Athanasou, N; Balke, M; Campanacci, L; Gebert, C; Gibbons, M; Hogendoorn, P; Kroep, J; Picci, P; Taylor, R; Wass, J | 1 |
| Aapro, M; Coleman, R; Gnant, M; Hadji, P; Lipton, A | 1 |
| Pozzi, S; Raje, N | 1 |
| Lanigan, LG; Martin, CK; Rosol, TJ; Thudi, NK; Toribio, RE; Werbeck, JL; Wolfe, TD | 1 |
| Black, DM; Bucci-Rechtweg, C; Grbic, JT; Lyles, KW; McClung, M; Orwoll, E; Reid, DM; Su, G | 1 |
| Keech, F; May, RJ; McLernon, DJ; Reid, DM; Rogers, MJ; Simpson, WG; Thompson, K; Vinod, K | 1 |
| Brennan, O; Kennedy, OD; Lee, TC; McNamara, LM; O'Brien, FJ; Rackard, SM | 1 |
| Berd, Y; He, W; Jensen, AB; Lombardi, A; Mehta, A; Ramirez, G; Song, Y; Wang, H; Wynne, C | 1 |
| Hadji, P | 2 |
| Ikebe, T; Kajiya, H; Kimachi, K; Nakayama, S; Okabe, K | 1 |
| Bargagli, G; Conca, R; Cozzolino, A; Fiaschi, AI; Francini, E; Francini, F; Gotti, G; Martellucci, I; Miano, ST; Migali, C; Pascucci, A; Petrioli, R | 1 |
| Chen, LK; Hou, X; Huang, Y; Li, S; Liao, H; Liu, JL; Xu, F; Xue, C; Zhang, L; Zhao, HY; Zhao, YY | 1 |
| Green, JR; Guenther, A | 1 |
| Chen, Y; Liang, X; Liu, D; Meng, YH; Peng, Y; Wang, H | 1 |
| Koul, HK; Koul, S; Meacham, RB | 1 |
| Ashton, JM; Becker, MW; Calvi, LM; Frisch, BJ; Jordan, CT; Xing, L | 1 |
| Athanasou, NA; Cheng, X; Estrada, FM; Gordon, S; Hemingway, F; Knowles, HJ | 1 |
| Aro, HT; Heervä, E; Peltonen, J; Peltonen, S; Svedström, E; Väänänen, K | 1 |
| Amodeo, V; Bazan, V; Caruso, S; Corsini, LR; Di Gaudio, F; Fanale, D; Insalaco, L; Margarese, N; Russo, A; Santini, D; Terrasi, M | 1 |
| Bauer, DC; Schousboe, JT | 1 |
| Hsu, LH; Lin, FH; Lu, DH; Wang, CC; Wu, CC; Yang, KC | 1 |
| Draenert, GF; Huetzen, DO; Kämmerer, PW; Nacu, V; Palarie, V; Wagner, W | 1 |
| De Stefano, V; Logroscino, CA; Proietti, L; Scaramuzzo, L; Tamburrelli, FC | 1 |
| Bolland, MJ; Gamble, G; Grey, A; Horne, A; House, M; Reid, IR; Wattie, D | 1 |
| Brown, R; Cohen, A; Mancini, D; McMahon, DJ; Pandit, K; Restaino, S; Shane, E; Staron, RB; Stein, EM; Verna, EC; Young, P; Zhang, C | 1 |
| Cornish, J; Dalbeth, N; Horne, A; House, ME; Pool, B; Reid, IR; Stewart, A | 1 |
| Scott, DF; Smith, RR; Woltz, JN | 1 |
| Chang, SX; Fan, JZ; He, YM; Li, GW; Tian, YN; Xu, Z | 1 |
| Belfrage, O; Isaksson, H; Tägil, M | 1 |
| Body, JJ; Brown, J; Coleman, R; Cook, R; Lipton, A; Smith, M | 1 |
| Cataldo, VD; Dong, W; Fanale, MA; Fayad, LE; Fowler, N; Hagemeister, FB; Jimenez, C; Kwak, LW; McLaughlin, P; Murphy, WA; Neelapu, S; Pro, B; Romaguera, J; Samaniego, F; Sanjorjo, P; Shah, J; Thompson, MA; Toth, B; Westin, JR | 1 |
| Hortobagyi, GN | 1 |
| Hussar, DA | 1 |
| Chen, B; Chin, JL; Gleason, DM; Goas, JA; Lacombe, L; Murray, R; Saad, F; Tchekmedyian, S; Venner, P; Vinholes, JJ | 1 |
| Major, P | 1 |
| Berenson, JR | 3 |
| Goa, KL; Wellington, K | 1 |
| Harland, SJ; Oosterlinck, W; Rosen, L | 1 |
| Evans, GP; Glatt, M; Green, JR; Hornby, SB; Hornby, SL; Pataki, A | 1 |
| Green, JR | 2 |
| Saad, F | 3 |
| Rosen, LS | 1 |
| Chung, G; Keen, RW | 1 |
| Denoyelle, C; Hong, L; Soria, C; Soria, J; Vannier, JP | 1 |
| Chole, RA; Ebmeyer, J; Faddis, BT; Hildmann, H; Jung, JY; Sudhoff, H | 1 |
| Pitts, WR | 1 |
| Avvisati, G; Battistoni, F; Borzomati, D; Coppola, R; Dicuonzo, G; Gavasci, M; Rocci, L; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Coleman, R; Croucher, P; Jagdev, S | 1 |
| Fraser, WD; Mishra, V; Peter, R | 1 |
| Evans, GP; Glatt, M; Green, JR; Hornby, SB; Pataki, A | 1 |
| Beer, TM; Garzotto, M; Tiffany, NM; Wersinger, EM | 1 |
| Bartsch, R; Hussian, D; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Figgitt, DP; Perry, CM | 1 |
| Goldring, SR; Gravallese, EM | 1 |
| Bergmeister, H; Gasser, J; Görtz, B; Hayer, S; Herrak, P; Kollias, G; Redlich, K; Reiter, E; Schett, G; Smolen, JS | 1 |
| Gillespie, MT; Glatt, M; Green, JR; Martin, TJ; Romas, E; Schlict, S; Sims, NA | 1 |
| Bukowski, RM; Colombo-Berra, A; Lipton, A; Rosen, L; Urbanowitz, G; Zheng, M | 1 |
| Parker, CC | 1 |
| Ambler, G; Cowell, CT; Högler, W; Little, D; McQuade, M; Yap, F | 1 |
| Decker, JL; Henderson, C; Hohneker, JA; Kaplan, BH; Lacerna, L; Orlowski, R; Purdy, MH; Schnell, FM; Vogel, CL; Wood, AJ; Yanagihara, RH | 1 |
| Alonso, B; Bouler, JM; Bujoli, B; Daculsi, G; Faucheux, C; Gauthier, O; Grimandi, G; Guicheux, JJ; Janvier, P; Josse, S; Laïb, S; Massiot, D; Pilet, P; Soueidan, A | 1 |
| Harvey, HA | 1 |
| Brahmbhatt, V; Patel, K; Ramu, V | 1 |
| Gralow, J | 1 |
| Cortizo, AM; McCarthy, AD; Vaisman, DN | 1 |
| Lipton, A | 2 |
| Schwartz, JE | 1 |
| Brown, JE; Coleman, RE; Cook, R; Hei, YJ; Lee, KA; Lipton, A; Major, P; Saad, F; Seaman, J; Smith, M; Zheng, M | 1 |
| Bereiter, H; Heckelei, A; Henschke, F; Hilken, G; Löer, F; Saxler, G; Sprecher, C; von Knoch, F; von Knoch, M; Wedemeyer, C | 1 |
| Little, DG; McDonald, M; McEvoy, T; Peat, R; Sharpe, IT; Williams, P | 1 |
| Alimonti, A; Bordignon, V; Carlini, P; Cognetti, F; Cordiali Fei, P; D'Agosto, G; Di Cocco, B; Di Cosimo, S; Fabi, A; Ferretti, G; Giannarelli, D; Papaldo, P; Salesi, N; Trento, E | 1 |
| Deftos, LJ | 1 |
| Briody, JN; Eisman, JA; Gardiner, EM; Little, DG; McEvoy, A; Smith, EJ; Smith, NC | 1 |
| Lipton, A; Saad, F | 2 |
| Fietkau, R; Gundlach, KK; Lenz, JH; Mueller, PC; Schmidt, W; Steiner-Krammer, B | 1 |
| Rizzoli, R; Uebelhart, B | 1 |
| Barkley, CS; Bilhartz, DL; Given, RW; Julian, SR; Karlin, GS; Lacerna, LV; McWhorter, LT; Metzger, C; Polascik, TJ; Vestal, JC | 1 |
| Arcara, C; Badalamenti, G; Casuccio, A; Cicero, G; Di Fede, G; Fulfaro, F; Gebbia, N; Intrivici, C; Leto, G; Rini, GB; Russo, A; Valerio, MR; Vitale, A | 1 |
| Suzuki, M; Tomoo, T | 1 |
| Hosking, D | 1 |
| Cornford, P; Manikandan, R; Mistry, R; Philip, J | 1 |
| Baccarani, M; Boni, P; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; Parente, R; Perrone, G; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E | 1 |
| Aspenberg, P; Astrand, J; Tägil, M | 1 |
| Kaise, H; Kohno, N | 1 |
| Angeletti, S; Brown, JE; Budillon, A; Caraglia, M; Coleman, RE; Dicuonzo, G; Hannon, RA; Holen, I; La Cesa, A; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Anjrini, AA; Badran, Z; Bouler, JM; Daculsi, G; Faucheux, C; Grimandi, G; Guicheux, J; Pilet, P; Soueidan, A | 1 |
| Brufsky, A | 1 |
| Aspenberg, P; Astrand, J; Harding, AK; Tägil, M | 1 |
| D'Souza, AB; Ebeling, PR; Grigg, AP; Szer, J | 1 |
| Barrick, M | 1 |
| Anagnostopoulos, A; Kiamouris, C; Konstantopoulos, K; Spyropoulou, E; Stoupa, E; Terpos, E; Voskaridou, E | 1 |
| Greiner, S; Kadow-Romacker, A; Lübberstedt, M; Schmidmaier, G; Wildemann, B | 1 |
| Carlsten, H; Ohlsson, C; Tarkowski, A; Verdrengh, M | 1 |
| Bandeira, F; Colares, V; Griz, L | 1 |
| Sakurai, T | 1 |
| Iguchi, H | 1 |
| Beamer, E; Kriegman, A; Lindsay, R; Saag, K; Zhou, W | 1 |
| Loveridge, N; Poole, KE; Reeve, J; Rose, CM; Warburton, EA | 1 |
| Ballard, P; Beck, T; BrintzenhofeSzoc, K; Caminis, J; Dapthary, M; Shapiro, J; Smith, B | 1 |
| Gondo, T; Hashimoto, T; Matsunaga, T; Shigetomi, M; Sugiyama, T; Suzuki, H; Taguchi, T; Tanaka, H | 1 |
| Bilezikian, JP; Borba, VZ; Kulak, CA; Paz-Filho, G; Seibel, MJ | 1 |
| Armstrong, A; Branstetter, D; Bussiere, J; Cowan, L; Dougall, WC; Jones, J; Kennedy, B; Miller, RE | 1 |
| Kim, HW; Lee, JI | 1 |
| Fratto, E; Galluzzo, S; Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B | 1 |
| Robb-Nicholson, C | 1 |
| Eagleton, MC; Hirbe, AC; Morgan, EA; Piwnica-Worms, D; Prior, JL; Rubin, J; Uluçkan, O; Weilbaecher, KN | 1 |
| Auriola, S; Holen, I; Kuokkanen, J; Mönkkönen, H; Mönkkönen, J; Ottewell, PD | 1 |
| Arlen, PM; Dahut, WL; Gulley, JL; Wu, S | 1 |
| Suzuki, Y | 1 |
| Bundred, N; Hadji, P | 1 |
| Bateman, TA; Lloyd, SA; Lu, T; Travis, ND | 1 |
| McKeage, K; Plosker, GL | 1 |
| Brufsky, AM | 2 |
| Brouwers, JE; Gasser, JA; Huiskes, R; Lambers, FM; van Rietbergen, B | 1 |
| Dhillon, S; Lyseng-Williamson, KA | 1 |
| Dai, R; Guo, H; Li, S; Liao, E; Liu, J; Sheng, Z; Wen, G; Wu, X; Xu, K | 1 |
| Bagan, JV; Gómez, D; Jiménez, Y; Poveda, R; Scully, C; Sirera, R | 1 |
| Arshad, MD; Bouler, JM; Bujoli, B; Faucheux, C; Guicheux, J; Janvier, P; Josse, S; Pilet, P; Soueidan, A; Verron, E | 1 |
| Brown, JE; Coleman, RE; Cook, R; Garnero, P; Lipton, A; Major, P; Saad, F; Terpos, E | 1 |
| Dai, RC; Jiang, YB; Liao, EY; Liu, JH; Ma, YL; Sheng, ZF; Xu, K; Zhang, YH | 1 |
| Braidman, IP; Evans, CE | 1 |
| Green, JR; Jaeggi, KA; Müller, K | 1 |
| Green, J | 1 |
| Arden-Cordone, M; Knieriem, A; Lyles, KW; Newton, RA; Schaffer, V; Siris, ES; Zelenakas, K | 1 |
| Ziegler, J | 1 |
| Binkley, N; Bruner, J; Davidowitz, B; Green, J; Haffa, A; Kimmel, D; Meng, C; Schaffer, V | 1 |
| Birbara, CA; Buckler, H; Davie, M; Fogelman, I; Fraser, W; Hosking, D; Lyles, K; Maricic, MJ; Moses, AM; Richardson, P; Ryan, W; Seaman, J; Selby, P; Singer, F; Siris, E; Zelenakas, K | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Amiot, M; Barillé, S; Bataille, R; Berthaud, P; Collette, M; Derenne, S; Harousseau, JL; Robillard, N | 1 |
| Berenson, JR; Conde, F; Henick, K; Nishikubo, C; Rettig, M; Swift, RA; Vescio, R; Von Teichert, JM | 1 |
| Berenson, JR; Coleman, RE; Dreicer, R; Howell, A; Kuross, SA; Lipton, A; Morley, W; Porter, L; Rosen, LS; Seaman, JJ | 1 |
| Berenson, JR; Givant, E; Harvey, H; Hupkes, M; Lipton, A; Rosen, LS; Savage, A; Swift, R; Vescio, RA; VonTeichert, JM; Woo, M | 1 |
| Cheer, SM; Noble, S | 1 |
55 review(s) available for zoledronic acid and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Bisphosphonate-loaded bone cement: Background, clinical indications and future perspectives.
Topics: Bone Cements; Bone Resorption; Diphosphonates; Humans; Orthopedic Procedures; Zoledronic Acid | 2022 |
Effects of bisphosphonates on osteoporosis: Focus on zoledronate.
Topics: Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Humans; Osteoporosis; Treatment Outcome; Zoledronic Acid | 2021 |
Therapeutic approaches for protecting bone health in patients with breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Denosumab; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Practice Guidelines as Topic; Spinal Cord Compression; Zoledronic Acid | 2018 |
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Zoledronic Acid | 2019 |
[Biomarkers of bone remodelling].
Topics: Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Denosumab; Diphosphonates; Humans; Imidazoles; Predictive Value of Tests; Zoledronic Acid | 2013 |
Male hypogonadism and skeletal health.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Biomarkers; Bone and Bones; Bone Density; Bone Resorption; Denosumab; Diphosphonates; Humans; Hypogonadism; Imidazoles; Immunologic Factors; Klinefelter Syndrome; Male; Men's Health; Osteoporosis; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Testosterone; Zoledronic Acid | 2013 |
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Clodronic Acid; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Immune System; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Treatment Outcome; Zoledronic Acid | 2015 |
[Newly developed drugs for osteoporosis in overseas and their future roles for the therapy].
Topics: Anabolic Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Resorption; Denosumab; Diphosphonates; Drug Design; Evidence-Based Medicine; Fractures, Bone; Humans; Imidazoles; Indoles; Organometallic Compounds; Osteoporosis; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Zoledronic Acid | 2008 |
[Update on treatment of postmenopausal osteoporosis].
Topics: Bone Resorption; Calcium; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Zoledronic Acid | 2008 |
Bisphosphonates in breast cancer: teaching an old dog new tricks.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis; Treatment Outcome; Zoledronic Acid | 2009 |
Dosing of zoledronic acid throughout the treatment continuum in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Drug Dosage Calculations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Injections, Intravenous; Neoplasm Staging; Osteoporosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome; Zoledronic Acid | 2011 |
Managing bone health with zoledronic acid: a review of randomized clinical study results.
Topics: Antineoplastic Agents; Bone and Bones; Bone Demineralization, Pathologic; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Drug Monitoring; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Postmenopause; Randomized Controlled Trials as Topic; Zoledronic Acid | 2011 |
The backbone of progress--preclinical studies and innovations with zoledronic acid.
Topics: Animals; Apoptosis; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Imidazoles; Mice; Multiple Myeloma; Neovascularization, Pathologic; Osteoclasts; Zoledronic Acid | 2011 |
New developments for treatment and prevention of bone metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Neoplasm Recurrence, Local; Osteonecrosis; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2011 |
New role for an established drug? Bisphosphonates as potential anticancer agents.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Clinical Trials as Topic; Diphosphonates; Drug Synergism; Female; Humans; Imidazoles; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Osteoclasts; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid | 2012 |
Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Monitoring, Physiologic; Osteoporotic Fractures; Raloxifene Hydrochloride; Wound Healing; Zoledronic Acid | 2012 |
Novel approaches to the management of bone metastases in patients with breast cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2002 |
The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Topics: Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pamidronate; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2002 |
Advances in the biology and treatment of myeloma bone disease.
Topics: Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; Intercellular Signaling Peptides and Proteins; Lymphokines; Membrane Glycoproteins; Multiple Myeloma; Osteoprotegerin; Pamidronate; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Zoledronic Acid | 2002 |
Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Humans; Hypercalcemia; Imidazoles; Kidney; Zoledronic Acid | 2003 |
Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid | 2002 |
Preclinical pharmacology of zoledronic acid.
Topics: Animals; Bone Density; Bone Neoplasms; Bone Remodeling; Bone Resorption; Diphosphonates; Drug Evaluation, Preclinical; Humans; Imidazoles; Zoledronic Acid | 2002 |
Treatment of hypercalcemia of malignancy with bisphosphonates.
Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid | 2002 |
Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imidazoles; Male; Palliative Care; Prostatic Neoplasms; Zoledronic Acid | 2002 |
Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Palliative Care; Zoledronic Acid | 2002 |
The anti-tumor potential of zoledronic acid.
Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Male; Mice; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Zoledronic Acid | 2003 |
Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Infusions, Intravenous; Osteoblasts; Osteolysis; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2003 |
Zoledronic acid: a review of its use in patients with advanced cancer.
Topics: Area Under Curve; Bone and Bones; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Drug Tolerance; Economics, Pharmaceutical; Female; Half-Life; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Male; Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2004 |
Bisphosphonates: environmental protection for the joint?
Topics: Animals; Arthritis; Arthritis, Rheumatoid; Bone Resorption; Collagen; Diphosphonates; Disease Progression; Imidazoles; Osteoclasts; Zoledronic Acid | 2004 |
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Neoplasm Metastasis; Osteolysis; Zoledronic Acid | 2004 |
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Pamidronate; Postmenopause; Triazoles; Zoledronic Acid | 2004 |
Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Osteonecrosis; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; United States; Women's Health; Zoledronic Acid | 2005 |
New therapeutic agents for the treatment of bone diseases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Topics: Aged; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Pain; Prostatic Neoplasms; Zoledronic Acid | 2005 |
[Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Calcitriol; Cells, Cultured; Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Geranyltranstransferase; Humans; Hypercalcemia; Imidazoles; Neoplasms; Osteoclasts; Zoledronic Acid | 2005 |
Pharmacological therapy of Paget's and other metabolic bone diseases.
Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Osteitis Deformans; Osteogenesis; Risedronic Acid; Zoledronic Acid | 2006 |
Zoledronic acid: past, present and future roles in cancer treatment.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2005 |
[Bisphosphonates for bone metastasis of malignant tumor].
Topics: Bone Neoplasms; Bone Resorption; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Evidence-Based Medicine; Humans; Imidazoles; Membrane Glycoproteins; Osteoclasts; Pain; Quality of Life; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Zoledronic Acid | 2006 |
Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Premenopause; Randomized Controlled Trials as Topic; Zoledronic Acid | 2006 |
[Treatment of Paget's disease of bone: importance of the zoledronic acid].
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Diphosphonates; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteitis Deformans; Pamidronate; Remission Induction; Treatment Outcome; Zoledronic Acid | 2006 |
[Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
Topics: Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Osteoporosis, Postmenopausal; Zoledronic Acid | 2007 |
[Molecular mechanism and potential targets for bone metastasis].
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Mice; Mice, Nude; Neoplastic Cells, Circulating; Osteolysis; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2007 |
New developments of aminobisphosphonates: the double face of Janus.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2007 |
Reducing the risk of bone loss associated with breast cancer treatment.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Risk Factors; Women's Health; Zoledronic Acid | 2007 |
[Secondary osteoporosis. Bisphosphonates as a possible strategy for the prevention of bone destruction in rheumatoid arthritis].
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Methotrexate; Osteoclasts; Zoledronic Acid | 2007 |
New research findings on zoledronic acid: survival, pain, and anti-tumour effects.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Urogenital Neoplasms; Zoledronic Acid | 2008 |
Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Risk Factors; Zoledronic Acid | 2007 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid | 2008 |
Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Neoplasm Staging; Neoplasms, Hormone-Dependent; Premenopause; Randomized Controlled Trials as Topic; Zoledronic Acid | 2007 |
Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Zoledronic Acid | 2008 |
Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2008 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies.
Topics: Animals; Bone and Bones; Bone Resorption; Diphosphonates; Drug Evaluation, Preclinical; Humans; Imidazoles; Models, Animal; Osteoporosis; Zoledronic Acid | 2001 |
Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2001 |
Zoledronic acid.
Topics: Animals; Bone and Bones; Bone Resorption; Calcium; Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Neoplasms; Zoledronic Acid | 2001 |
49 trial(s) available for zoledronic acid and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.
Topics: Biomarkers; Bone Density; Bone Resorption; Denosumab; Humans; Osteoclasts; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2023 |
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Denosumab; Female; Femur Neck; Fractures, Bone; Humans; Middle Aged; Withholding Treatment; Zoledronic Acid | 2019 |
Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic Acid.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Female; Humans; Lumbar Vertebrae; Male; Osteoporosis; Osteoporotic Fractures; Risk Factors; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2021 |
Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lumbar Vertebrae; Male; Models, Biological; Osteoporosis; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2018 |
Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial.
Topics: Administration, Intravenous; Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Middle Aged; Premenopause; Prospective Studies; Time Factors; Treatment Outcome; Young Adult; Zoledronic Acid | 2018 |
A Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year after Kidney Transplantation.
Topics: Adult; Bone Density Conservation Agents; Bone Resorption; Female; Humans; Kidney Transplantation; Male; Postoperative Complications; Prospective Studies; Zoledronic Acid | 2019 |
Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Calcitriol; Calcium Carbonate; Drug Therapy, Combination; Female; Follow-Up Studies; Hip Prosthesis; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postoperative Care; Single-Blind Method; Zoledronic Acid | 2019 |
Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
Topics: Adaptor Proteins, Signal Transducing; Aged; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Bone Regeneration; Bone Resorption; Calcium Carbonate; Cholecalciferol; Collagen Type I; Combined Modality Therapy; Dietary Supplements; Diphosphonates; Female; Genetic Markers; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; PAX5 Transcription Factor; Peptides; Time Factors; Zoledronic Acid | 2013 |
Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
Topics: Aged; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Hip; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Peptides; Procollagen; Spine; Zoledronic Acid | 2014 |
Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Middle Aged; Transplantation, Homologous; Treatment Outcome; Young Adult; Zoledronic Acid | 2013 |
Identification of the risk factors associated with hypocalcemia induced by denosumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Resorption; Calcium; Creatinine; Denosumab; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Logistic Models; Male; Middle Aged; Neoplasms; Odds Ratio; Osteoclasts; RANK Ligand; Retrospective Studies; Risk Factors; ROC Curve; Zoledronic Acid | 2013 |
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Denosumab; Diphosphonates; Disease Progression; Double-Blind Method; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasms; Pain; Treatment Outcome; Zoledronic Acid | 2014 |
Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Foot Bones; Gout; Humans; Imidazoles; Male; Middle Aged; Spine; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2014 |
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
Topics: Aged; Anabolic Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Hypertension; Imidazoles; Intercellular Signaling Peptides and Proteins; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Osteolysis; Recurrence; Spinal Cord Compression; Zoledronic Acid | 2014 |
Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis.
Topics: Aged; Asian People; Biomarkers; Body Temperature; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Demography; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteogenesis; Osteoporosis; Single-Blind Method; Zoledronic Acid | 2017 |
Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2009 |
Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury.
Topics: Adolescent; Adult; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Hip Joint; Humans; Imidazoles; Lumbar Vertebrae; Male; Osteoporosis; Spinal Cord Injuries; Young Adult; Zoledronic Acid | 2011 |
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Letrozole; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Survival Rate; Time Factors; Treatment Outcome; Triazoles; Zoledronic Acid | 2010 |
Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Placebos; Postmenopause; Zoledronic Acid | 2010 |
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Collagen Type I; Databases as Topic; Diphosphonates; Female; Follow-Up Studies; Forecasting; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Osteonecrosis; Osteoporosis, Postmenopausal; Peptides; Placebos; Prevalence; Risk Factors; United States; Zoledronic Acid | 2010 |
Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.
Topics: Acute-Phase Reaction; Anticholesteremic Agents; Bone Density Conservation Agents; Bone Resorption; Cholesterol; Cytokines; Diphosphonates; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Imidazoles; Indoles; Injections, Intravenous; Middle Aged; Postmenopause; T-Lymphocytes; Zoledronic Acid | 2011 |
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
Topics: Adult; Biomarkers; Biphenyl Compounds; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cathepsin K; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Treatment Outcome; Zoledronic Acid | 2010 |
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Peptides; Treatment Outcome; Zoledronic Acid | 2011 |
Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Nasopharyngeal Neoplasms; Peptides; Treatment Outcome; Zoledronic Acid | 2011 |
Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Peptide Fragments; Peptides; Procollagen; Time Factors; Zoledronic Acid | 2012 |
Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
Topics: Adult; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Heart Transplantation; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Placebos; Postoperative Care; Postoperative Complications; Zoledronic Acid | 2012 |
No reduction in circulating preosteoclasts 18 months after treatment with zoledronate: analysis from a randomized placebo controlled trial.
Topics: Acid Phosphatase; Aged; Bone Density Conservation Agents; Bone Resorption; CD11b Antigen; Diphosphonates; Female; Flow Cytometry; Humans; Imidazoles; Isoenzymes; Leukocytes, Mononuclear; Lipopolysaccharide Receptors; Macrophage Colony-Stimulating Factor; Middle Aged; Osteoclasts; Osteoporosis; Placebos; RANK Ligand; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2013 |
Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty: preliminary results of a prospective randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Femur; Humans; Imidazoles; Male; Middle Aged; Postoperative Complications; Prospective Studies; Time Factors; Zoledronic Acid | 2013 |
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Female; Humans; Imidazoles; Lymphoma; Male; Middle Aged; Neoplasm Staging; Treatment Outcome; Young Adult; Zoledronic Acid | 2013 |
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid | 2002 |
Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Palliative Care; Zoledronic Acid | 2002 |
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Diseases; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Drug Therapy, Combination; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Pain; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Treatment Failure; Zoledronic Acid | 2004 |
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Neoplasm Metastasis; Osteolysis; Zoledronic Acid | 2004 |
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
Topics: Aged; Arthralgia; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Creatinine; Diphosphonates; Fatigue; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Nausea; Pain; Pain Measurement; Prospective Studies; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid | 2004 |
Zoledronic acid prevents cancer treatment-induced bone loss.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2005 |
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
Topics: Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cytokines; Diphosphonates; Female; Fibroblast Growth Factor 2; Humans; Imidazoles; Interferon-gamma; Interleukins; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Metalloproteases; Middle Aged; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2005 |
CALGB 78909: Phase III trial of intravenous zoledronic acid in the prevention of bone loss in localized breast cancer patients with chemotherapy-induced ovarian failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Resorption; Breast Neoplasms; Clinical Protocols; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Primary Ovarian Insufficiency; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Zoledronic Acid | 2005 |
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Pain; Pain Measurement; Prostatic Neoplasms; Zoledronic Acid | 2005 |
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Collagen Type I; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Pain; Peptides; Thalidomide; Treatment Outcome; Zoledronic Acid | 2006 |
Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial.
Topics: beta-Thalassemia; Bone Density; Bone Resorption; Diphosphonates; Humans; Imidazoles; Osteoporosis; Placebos; Treatment Outcome; Zoledronic Acid | 2006 |
A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Resorption; Collagen Type I; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Peptides; Postmenopause; Surveys and Questionnaires; Time Factors; Zoledronic Acid | 2007 |
A single infusion of zoledronate prevents bone loss after stroke.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Hemiplegia; Humans; Imidazoles; Male; Middle Aged; Stroke; Zoledronic Acid | 2007 |
Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury.
Topics: Adolescent; Adult; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Femur; Femur Neck; Humans; Imidazoles; Male; Spinal Cord Injuries; Zoledronic Acid | 2007 |
Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Resorption; Calcium; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hydroxyproline; Imidazoles; Infusions, Intravenous; Male; Osteitis Deformans; Zoledronic Acid | 1997 |
Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone Resorption; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hydroxyproline; Imidazoles; Infusions, Intravenous; Male; Osteitis Deformans; Zoledronic Acid | 1999 |
A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
Topics: Adult; Aged; Anorexia; Biomarkers; Bone Neoplasms; Bone Resorption; Constipation; Diphosphonates; Female; Fever; Humans; Imidazoles; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Pain; Treatment Outcome; Zoledronic Acid | 2001 |
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Collagen; Collagen Type I; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Pamidronate; Peptides; Zoledronic Acid | 2001 |
A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
Topics: Adult; Aged; Bone Neoplasms; Bone Resorption; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors; Zoledronic Acid | 2001 |
157 other study(ies) available for zoledronic acid and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats | 2002 |
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques; Kidney; Mice; Pamidronate; Parathyroidectomy; Rats; Skull; Structure-Activity Relationship; Thyroidectomy; Zoledronic Acid | 2002 |
A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents.
Topics: Alendronate; Bone Resorption; Diphosphonates; Heterocyclic Compounds; Models, Molecular; Pamidronate; Quantitative Structure-Activity Relationship | 2003 |
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Dictyostelium; Diphosphonates; Geranyltranstransferase; Humans; In Vitro Techniques; Leishmania major; Metatarsal Bones; Mice; Models, Molecular; Pyridinium Compounds; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; Trypanocidal Agents | 2005 |
Novel 2,7-Diazaspiro[4,4]nonane Derivatives to Inhibit Mouse and Human Osteoclast Activities and Prevent Bone Loss in Ovariectomized Mice without Affecting Bone Formation.
Topics: Alkanes; Animals; Bone Resorption; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Inbred C57BL; Osteoclasts; Osteogenesis; Ovariectomy | 2020 |
Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways.
Topics: Animals; Bone Density; Bone Resorption; Cell Differentiation; Gene Expression Regulation; MAP Kinase Kinase 4; Mice; NF-kappa B; NFATC Transcription Factors; Osteogenesis; Phosphorylation; RANK Ligand; RAW 264.7 Cells; Signal Transduction; Zoledronic Acid | 2022 |
Effects of Anti-Receptor Activator of Nuclear Factor Kappa B Ligand Antibody and Zoledronic Acid on Periapical Lesion Development in Mice.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Inflammation; Mice; NF-kappa B; Osteoclasts; RANK Ligand; Zoledronic Acid | 2022 |
Inhibition of osteoclastogenesis after bisphosphonate therapy discontinuation: an in vitro approach.
Topics: Animals; Bone and Bones; Bone Resorption; Diphosphonates; Mice; Osteoclasts; Osteogenesis; Zoledronic Acid | 2022 |
Zoledronic acid generates a spatiotemporal effect to attenuate osteoarthritis by inhibiting potential Wnt5a-associated abnormal subchondral bone resorption.
Topics: Animals; Bone Resorption; Cartilage, Articular; Disease Models, Animal; Male; Osteoarthritis; Rats; Wnt-5a Protein; X-Ray Microtomography; Zoledronic Acid | 2022 |
Bisphosphonate type-dependent cell viability suppressive effects of carbon nanohorn-calcium phosphate-bisphosphonate nanocomposites.
Topics: Animals; Bone Neoplasms; Bone Resorption; Calcium Phosphates; Carbon; Cell Survival; Diphosphonates; Drug Carriers; Ibandronic Acid; Mice; Nanocomposites; Osteoclasts; Pamidronate; Reactive Oxygen Species; Zoledronic Acid | 2022 |
Effect of oral zoledronate administration on bone turnover in older women.
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Zoledronic Acid | 2023 |
The nanoformula of zoledronic acid and calcium carbonate targets osteoclasts and reverses osteoporosis.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Calcium Carbonate; Mice; Osteoclasts; Osteoporosis; Zoledronic Acid | 2023 |
A Dual-Targeted Metal-Organic Framework Based Nanoplatform for the Treatment of Rheumatoid Arthritis by Restoring the Macrophage Niche.
Topics: Arthritis, Rheumatoid; Bone Resorption; Delayed-Action Preparations; Humans; Macrophages; Metal-Organic Frameworks; Osteoclasts; Zoledronic Acid | 2023 |
A Machine Learning-Based Image Segmentation Method to Quantify In Vitro Osteoclast Culture Endpoints.
Topics: Acid Phosphatase; Animals; Bone Resorption; Cell Differentiation; Cells, Cultured; Coculture Techniques; Mice; Osteoclasts; Tartrate-Resistant Acid Phosphatase; Ticagrelor; Zoledronic Acid | 2023 |
Zoledronic acid epigenetically alleviates high-glucose-suppressed osteogenic differentiation of MC3T3-E1 cells.
Topics: Bone Resorption; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Epigenesis, Genetic; Glucose; Humans; MicroRNAs; Osteogenesis; Osteoporosis; RNA, Long Noncoding; Zoledronic Acid | 2023 |
Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Topics: Ankle; Anorexia; Antithyroid Agents; Aromatase Inhibitors; Arthralgia; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Collagen Type I; Denosumab; Deprescriptions; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Graves Disease; Humans; Hypercalcemia; Methimazole; Middle Aged; Parathyroid Hormone; Peptides; Potassium Iodide; Radionuclide Imaging; Tartrate-Resistant Acid Phosphatase; Thirst; Zoledronic Acid | 2020 |
Nanohydroxyapatite Based Ceramic Carrier Promotes Bone Formation in a Femoral Neck Canal Defect in Osteoporotic Rats.
Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Regeneration; Bone Resorption; Calcium Sulfate; Drug Carriers; Exosomes; Female; Femur Neck; Hip Fractures; Hydroxyapatites; Nanostructures; Osteogenesis; Osteoporosis; Rats, Sprague-Dawley; Recombinant Proteins; Transforming Growth Factor beta; X-Ray Microtomography; Zoledronic Acid | 2020 |
Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Denosumab; Disease Progression; Female; Follow-Up Studies; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Peptides; Prognosis; Prospective Studies; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2020 |
Modulation of bone formation and resorption using a novel zoledronic acid loaded gelatin nanoparticles integrated porous titanium scaffold: an in vitro and in vivo study.
Topics: Animals; Biocompatible Materials; Bone and Bones; Bone Regeneration; Bone Resorption; Cell Adhesion; Cell Differentiation; Cell Proliferation; Female; Gelatin; In Vitro Techniques; Nanoparticles; Osteoclasts; Osteogenesis; Osteoporosis; Porosity; Rabbits; Static Electricity; Tissue Scaffolds; Titanium; Zoledronic Acid | 2020 |
Zoledronate decreases CTLA-4 in vivo and in vitro independently of its action on bone resorption.
Topics: Bone Resorption; CTLA-4 Antigen; Diphosphonates; Female; Humans; Imidazoles; Leukocytes, Mononuclear; Zoledronic Acid | 2020 |
[Zoledronate regulates osteoclast differentiation and bone resorption in high glucose through p38 MAPK pathway].
Topics: Animals; Bone Resorption; Cell Differentiation; Glucose; MAP Kinase Signaling System; Mice; NFATC Transcription Factors; Osteoclasts; p38 Mitogen-Activated Protein Kinases; RANK Ligand; Zoledronic Acid | 2020 |
The effect of high concentration of zoledronic acid on tooth induced movement and its repercussion on root, periodontal ligament and alveolar bone tissues in rats.
Topics: Alveolar Process; Animals; Bone Density Conservation Agents; Bone Resorption; Drug Evaluation, Preclinical; Male; Osteoporosis; Periodontal Ligament; Rats, Wistar; Tooth Movement Techniques; Tooth Root; Zoledronic Acid | 2021 |
Zoledronic acid modulates osteoclast apoptosis through activation of the NF-κB signaling pathway in ovariectomized rats.
Topics: Animals; Apoptosis; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Cell Differentiation; Female; NF-kappa B; Osteoclasts; Osteogenesis; Osteoporosis; Ovariectomy; Rats, Sprague-Dawley; Signal Transduction; Zoledronic Acid | 2021 |
BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD.
Topics: Administration, Intravenous; Administration, Oral; Aged; Alendronate; Amino Acids; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Deprescriptions; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Time Factors; Treatment Failure; Zoledronic Acid | 2017 |
Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism.
Topics: Animals; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Imidazoles; Mice; Mice, Knockout; Nuclear Matrix-Associated Proteins; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Transcription Factors; Zoledronic Acid | 2017 |
Long-term therapy with intravenous zoledronate increases the number of nonattached osteoclasts.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cell Count; Diphosphonates; Imidazoles; Immunohistochemistry; Injections, Intravenous; Male; Osteoclasts; Osteogenesis; Osteoprotegerin; RANK Ligand; Rats; Tooth Extraction; Tooth Socket; Wound Healing; Zoledronic Acid | 2017 |
Dual modulation of bone formation and resorption with zoledronic acid-loaded biodegradable magnesium alloy implants improves osteoporotic fracture healing: An in vitro and in vivo study.
Topics: Absorbable Implants; Alloys; Animals; Biocompatible Materials; Bone Development; Bone Nails; Bone Resorption; Cell Differentiation; Cells, Cultured; Diphosphonates; Female; Femoral Fractures; Fracture Healing; Imidazoles; Magnesium; Mesenchymal Stem Cells; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Osteoporotic Fractures; Rats, Sprague-Dawley; Zoledronic Acid | 2018 |
Topical zoledronic acid decreases micromotion induced bone resorption in a sheep arthroplasty model.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Evaluation, Preclinical; Fibrosis; Imidazoles; Prosthesis Failure; Sheep; Zoledronic Acid | 2017 |
In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Topics: Adult; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cell Proliferation; Denosumab; Giant Cell Tumor of Bone; Humans; In Vitro Techniques; Male; Middle Aged; Osteoclasts; Prognosis; Tumor Cells, Cultured; Zoledronic Acid | 2019 |
Simple 3,4-Dihydroxy-L-Phenylalanine Surface Modification Enhances Titanium Implant Osseointegration in Ovariectomized Rats.
Topics: Animals; Bone Resorption; Bone-Anchored Prosthesis; Cell Differentiation; Coated Materials, Biocompatible; Dental Implantation, Endosseous; Dental Implants; Dental Prosthesis Design; Diphosphonates; Female; Osseointegration; Osteoclasts; Osteoporosis; Ovariectomy; Phenylalanine; Rats; Rats, Sprague-Dawley; Surface Properties; Titanium; Torque; X-Ray Microtomography; Zoledronic Acid | 2017 |
Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Body Weight; Bone Resorption; Dose-Response Relationship, Drug; Female; Femur; Osteocytes; Periodontitis; Prevalence; Sigmodontinae; Treatment Outcome; Zoledronic Acid | 2018 |
[Experimental study on inhibitory effect of zoledronic acid on the action style of the osteoclast].
Topics: Acid Phosphatase; Animals; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Cells, Cultured; Mice; Osteoclasts; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2017 |
New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Bone Resorption; Cell Line; HEK293 Cells; Hematopoiesis; Humans; Lymphopoiesis; Mice; Mice, Inbred C57BL; Osteoclasts; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RANK Ligand; Tumor Microenvironment; Zoledronic Acid | 2018 |
Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62
Topics: Aging; Animals; Bone and Bones; Bone Resorption; Calcification, Physiologic; Disease Models, Animal; Mice, Inbred C57BL; Mice, Mutant Strains; Mutation; Organ Size; Osteitis Deformans; Osteoclasts; Phenotype; Sequestosome-1 Protein; Zoledronic Acid | 2018 |
Zoledronic acid : Treatment option for Gorham-Stout disease.
Topics: Biopsy; Bone Resorption; Female; Humans; Middle Aged; Osteolysis, Essential; Treatment Outcome; Vitamin D; Zoledronic Acid | 2018 |
Zoledronate and high glucose levels influence osteoclast differentiation and bone absorption via the AMPK pathway.
Topics: AMP-Activated Protein Kinases; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Cell Movement; Cell Survival; Glucose; Mice; Osteoclasts; RAW 264.7 Cells; Signal Transduction; Zoledronic Acid | 2018 |
Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years.
Topics: Aged; Antineoplastic Agents, Hormonal; Asian People; Bone Density; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Denosumab; Female; Follow-Up Studies; Hong Kong; Humans; Incidence; Mastectomy; Middle Aged; Postmenopause; Radiotherapy, Adjuvant; Receptors, Estrogen; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid | 2018 |
Contribution of Inflammation and Bone Destruction to Pain in Arthritis: A Study in Murine Glucose-6-Phosphate Isomerase-Induced Arthritis.
Topics: Activating Transcription Factor 3; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Bone Resorption; Cyclic AMP Response Element-Binding Protein; Glucose-6-Phosphate Isomerase; Hindlimb; Hyperalgesia; Inflammation; Mice; Pain; T-Lymphocytes, Regulatory; TRPV Cation Channels; Zoledronic Acid | 2019 |
Zoledronate effects on systemic and jaw osteopenias in ovariectomized periostin-deficient mice.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Cell Adhesion Molecules; Diphosphonates; Female; Imidazoles; Jaw; Mice; Mice, Knockout; Ovariectomy; Tomography, X-Ray Computed; Zoledronic Acid | 2013 |
Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.
Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cat Diseases; Cats; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diphosphonates; Disease Models, Animal; Heterografts; Humans; Imidazoles; Male; Meloxicam; Mice; Mice, Nude; Mouth Neoplasms; Neoplasms, Squamous Cell; Random Allocation; Real-Time Polymerase Chain Reaction; RNA, Messenger; Thiazines; Thiazoles; Treatment Outcome; Zoledronic Acid | 2015 |
Zoledronic acid prevents loss of trabecular bone after focal irradiation in mice.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Humans; Imidazoles; Male; Mice; Radiation-Protective Agents; Radiotherapy; X-Rays; Zoledronic Acid | 2013 |
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Denosumab; Diphosphonates; Evidence-Based Medicine; Humans; Imidazoles; Internationality; Palliative Care; Treatment Outcome; Zoledronic Acid | 2013 |
Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Melphalan; Middle Aged; Multimodal Imaging; Osteolysis; Positron-Emission Tomography; Pyrazines; Recurrence; Remission Induction; Rituximab; Tomography, X-Ray Computed; Waldenstrom Macroglobulinemia; Zoledronic Acid | 2013 |
Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study.
Topics: Bone Neoplasms; Bone Resorption; Calcification, Physiologic; Cell Adhesion; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Humans; Imidazoles; Immunohistochemistry; Integrins; Jaw; Microscopy, Electron, Scanning; Mouth Mucosa; Osteonecrosis; Pamidronate; Sarcoglycans; Zoledronic Acid | 2013 |
Preclinical evaluation of zoledronate to maintain bone allograft and improve implant fixation in revision joint replacement.
Topics: Animals; Arthroplasty, Replacement, Knee; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Resorption; Bone Transplantation; Diphosphonates; Dogs; Female; Imidazoles; Knee Prosthesis; Postoperative Complications; Random Allocation; Reoperation; Transplantation, Homologous; Treatment Outcome; Zoledronic Acid | 2013 |
Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice.
Topics: Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Foscarnet; Imidazoles; Mice; Mice, Inbred BALB C; Molecular Structure; Necrosis; Osteitis; Phosphate Transport Proteins; Zoledronic Acid | 2013 |
Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats.
Topics: Abscess; Alveolar Process; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Models, Animal; Imidazoles; Injections, Intraperitoneal; Injections, Intravenous; Male; Maxilla; Molar; Osteoclasts; Osteosclerosis; Random Allocation; Rats; Rats, Wistar; Tooth Extraction; Zoledronic Acid | 2014 |
Upregulation of endogenous farnesyl diphosphate synthase overcomes the inhibitory effect of bisphosphonate on protein prenylation in Hela cells.
Topics: Bone Resorption; Diphosphonates; Gene Expression Regulation; Geranyltranstransferase; HeLa Cells; Humans; Imidazoles; Osteoclasts; Protein Prenylation; Sterol Regulatory Element Binding Protein 1; Zoledronic Acid | 2014 |
Effect of bisphosphonates on the rapidly growing male murine skeleton.
Topics: Alendronate; Animals; Apoptosis; Biomechanical Phenomena; Bone and Bones; Bone Development; Bone Resorption; Chondrocytes; Clodronic Acid; Diphosphonates; Hypertrophy; Imidazoles; Male; Mice; Mice, Inbred C57BL; Pamidronate; Phenotype; X-Ray Microtomography; Zoledronic Acid | 2014 |
Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
Topics: Animals; Bone Resorption; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chemokine CCL2; Diphosphonates; Humans; Imidazoles; Mice; Monocytes; Neoplasm Invasiveness; Osteoclasts; Osteogenesis; Osteolysis; Osteoprotegerin; Osteosarcoma; RANK Ligand; Zoledronic Acid | 2014 |
Early tissue responses to zoledronate, locally delivered by bone screw, into a compromised cancellous bone site: a pilot study.
Topics: Animals; Bone Resorption; Bone Screws; Coated Materials, Biocompatible; Diphosphonates; Drug Evaluation, Preclinical; Exudates and Transudates; Femur; Fibrin; Fibrinogen; Fibrosis; Imidazoles; Implants, Experimental; Macrophages; Male; Mesoderm; Osseointegration; Osteoclasts; Pilot Projects; Rabbits; Titanium; Zoledronic Acid | 2014 |
Mesoporous silica nanoparticles/hydroxyapatite composite coated implants to locally inhibit osteoclastic activity.
Topics: Animals; Bone Resorption; Bone Wires; Coated Materials, Biocompatible; Diphosphonates; Drug Carriers; Durapatite; Humans; Imidazoles; Nanoparticles; Osteoclasts; Porosity; Prostheses and Implants; Silicon Dioxide; Zoledronic Acid | 2014 |
Maximizing bone formation in posterior spine fusion using rhBMP-2 and zoledronic acid in wild type and NF1 deficient mice.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Resorption; Diphosphonates; Imidazoles; Mice; Mice, Knockout; Neurofibromatosis 1; Neurofibromin 1; Osteogenesis; Pseudarthrosis; Recombinant Proteins; Spinal Fusion; X-Ray Microtomography; Zoledronic Acid | 2014 |
Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.
Topics: Aged; Bone Density Conservation Agents; Bone Resorption; Cohort Studies; Comparative Effectiveness Research; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Propensity Score; Proportional Hazards Models; Registries; Survival Rate; Veterans; Zoledronic Acid | 2015 |
Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Collagen Type I; Cytokines; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteonecrosis; Pamidronate; Peptides; Prognosis; Zoledronic Acid | 2014 |
[The rescue effect of RANKL on zoledronate induced acid inhibition of osteoclastogenesis and gene expression of NF-kappaB p50 and c-Jun].
Topics: Animals; Bone Resorption; Cell Line; Diphosphonates; Gene Expression; Imidazoles; Mice; NF-kappa B p50 Subunit; Osteoblasts; Osteoclasts; Proto-Oncogene Proteins c-jun; RANK Ligand; Zoledronic Acid | 2014 |
Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Castration; Cell Line, Tumor; Diphosphonates; Humans; Imidazoles; Male; Mice, Inbred BALB C; Prostatic Neoplasms; Tumor Burden; Zoledronic Acid | 2014 |
Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.
Topics: Acid Phosphatase; Alveolar Process; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Resorption; Diphosphonates; Disease Models, Animal; Imidazoles; Isoenzymes; Male; Maxilla; Mice, Inbred C57BL; Periodontium; Radiography; Recombinant Fusion Proteins; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2014 |
Osteoclast inhibition impairs chondrosarcoma growth and bone destruction.
Topics: Animals; Bone and Bones; Bone Resorption; Chondrosarcoma; Diphosphonates; Imidazoles; Male; Osteoclasts; Parathyroid Hormone-Related Protein; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta2; Zoledronic Acid | 2014 |
Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-κB ligand antibody in mice.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Resorption; Denosumab; Diphosphonates; Disease Models, Animal; Imidazoles; Mice; Osteoclasts; RANK Ligand; Zoledronic Acid | 2014 |
Zoledronic acid at the time of castration prevented castration-induced bone metastasis in mice.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Castration; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2014 |
Does locally delivered Zoledronate influence peri-implant bone formation? - Spatio-temporal monitoring of bone remodeling in vivo.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Bone Screws; Diphosphonates; Drug Delivery Systems; Female; Femur; Hydrogel, Polyethylene Glycol Dimethacrylate; Imidazoles; Osteogenesis; Rats; Zoledronic Acid | 2014 |
[Zoledronate inhibits TRPV5 and NFATc1 expression during differentiation of osteoclasts].
Topics: Animals; Bone Resorption; Calcium Channels; Cell Differentiation; Cell Line; Diphosphonates; Down-Regulation; Imidazoles; Mice; NFATC Transcription Factors; Osteoclasts; RANK Ligand; RNA, Messenger; TRPV Cation Channels; Zoledronic Acid | 2014 |
Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss.
Topics: Animals; Antineoplastic Agents; Bone Density; Bone Remodeling; Bone Resorption; Chemokine CCL2; Cytokines; Diphosphonates; Hematopoiesis; Imidazoles; Inflammation; Inflammation Mediators; Mice, Inbred C57BL; Stem Cell Transplantation; Transplantation, Homologous; X-Ray Microtomography; Zoledronic Acid | 2015 |
Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Calcium; Cell Differentiation; Collagen Type I; Denosumab; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Osteoblasts; Osteocalcin; Osteogenesis; Peptides; RANK Ligand; Retrospective Studies; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2014 |
[Effect of zoledronate on the osteoclast adhesion and gene expression of integrin α(v) and β3].
Topics: Animals; Bone Resorption; Diphosphonates; Gene Expression; Imidazoles; Integrin alphaV; Mice; Osteoclasts; RNA, Messenger; Zoledronic Acid | 2014 |
OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
Topics: Abscess; Acid Phosphatase; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Resorption; Denosumab; Diphosphonates; Disease Models, Animal; Imidazoles; Immunoglobulin Fc Fragments; Isoenzymes; Male; Mandible; Maxilla; Mice; Mice, Inbred C57BL; Osteoclasts; Osteoprotegerin; RANK Ligand; Rats; Recombinant Fusion Proteins; Tartrate-Resistant Acid Phosphatase; X-Ray Microtomography; Zoledronic Acid | 2015 |
Diminished Progression of Periapical Lesions with Zoledronic Acid in Ovariectomized Rats.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Progression; Female; Imidazoles; Immunohistochemistry; Osteonecrosis; Ovariectomy; Periapical Periodontitis; Rats, Wistar; X-Ray Microtomography; Zoledronic Acid | 2015 |
Revival of nitrogen-containing bisphosphonate-induced inhibition of osteoclastogenesis and osteoclast function by water-soluble microfibrous borate glass.
Topics: Animals; Apoptosis; Bone Resorption; Borates; Cell Differentiation; Diphosphonates; Glass; Imidazoles; Macrophages; Mice; Microscopy, Electron, Transmission; Nitrogen; Osteoclasts; Osteonecrosis; Oxidative Stress; RANK Ligand; RAW 264.7 Cells; Reactive Oxygen Species; Risedronic Acid; Water; Zoledronic Acid | 2016 |
Zoledronate prevents lactation induced bone loss and results in additional post-lactation bone mass in mice.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Diphosphonates; Female; Femur; Fractures, Bone; Imidazoles; Lactation; Mice; Organ Size; Osteogenesis; Tartrate-Resistant Acid Phosphatase; Weaning; X-Ray Microtomography; Zoledronic Acid | 2016 |
Novel mutations in FKBP10 in Chinese patients with osteogenesis imperfecta and their treatment with zoledronic acid.
Topics: Adult; Asian People; Base Sequence; Bone Density; Bone Density Conservation Agents; Bone Resorption; Child; Child, Preschool; China; Collagen Type I; Collagen Type I, alpha 1 Chain; Diphosphonates; Female; Fractures, Bone; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; Male; Membrane Proteins; Osteogenesis Imperfecta; Sequence Analysis, DNA; Tacrolimus Binding Proteins; Young Adult; Zoledronic Acid | 2017 |
Effects of Bisphosphonate Administration on Cleft Bone Graft in a Rat Model.
Topics: Alveolar Process; Animals; Bone Resorption; Bone Transplantation; Diphosphonates; Female; Femur; Ilium; Imidazoles; Rats; Rats, Inbred F344; X-Ray Microtomography; Zoledronic Acid | 2017 |
Clomipramine causes osteoporosis by promoting osteoclastogenesis via E3 ligase Itch, which is prevented by Zoledronic acid.
Topics: Animals; Bone Marrow Cells; Bone Resorption; Cell Count; Clomipramine; Diphosphonates; Imidazoles; Mice, Inbred C57BL; Organ Size; Osteoclasts; Osteogenesis; Osteoporosis; Ubiquitin-Protein Ligases; Zoledronic Acid | 2017 |
Bisphosphonates in children with hypercalciuria and reduced bone mineral density.
Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Child; Creatinine; Diphosphonates; Female; Humans; Hypercalciuria; Imidazoles; Male; Phosphorus; Retrospective Studies; Zoledronic Acid | 2008 |
Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating.
Topics: Acid Phosphatase; Bone Density Conservation Agents; Bone Resorption; Cell Count; Cells, Cultured; Coated Materials, Biocompatible; Coculture Techniques; Collagen Type I; Collagen Type I, alpha 1 Chain; Diphosphonates; Humans; Imidazoles; Isoenzymes; Osteoblasts; Osteoclasts; Osteoprotegerin; Polyesters; RANK Ligand; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2009 |
Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
Topics: Acid Phosphatase; Animals; Bone and Bones; Bone Resorption; Breast Neoplasms; Cell Count; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Female; Humans; Imidazoles; Isoenzymes; Luminescent Measurements; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoclasts; Osteolysis; Osteoprotegerin; Radiography; Tartrate-Resistant Acid Phosphatase; Whole Body Imaging; Zoledronic Acid | 2009 |
A classical presentation of Paget disease of bone.
Topics: Aged; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Femur; Humans; Imidazoles; Male; Osteitis Deformans; Pelvis; Radiography; Zoledronic Acid | 2008 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Middle Aged; Multiple Myeloma; Necrosis; Osteoclasts; Osteonecrosis; Thalidomide; Zoledronic Acid | 2009 |
Zoledronate reduces unwanted bone resorption in intercalary bone allografts.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Regeneration; Bone Remodeling; Bone Resorption; Bone Transplantation; Diphosphonates; Disease Models, Animal; Femur; Graft Survival; Imidazoles; Male; Radiography; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Transplantation, Homologous; Zoledronic Acid | 2010 |
Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal; Humans; Hyperparathyroidism; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Transgenic; Osteoclasts; Osteoprotegerin; Porosity; Primary Myelofibrosis; Receptor, Parathyroid Hormone, Type 1; Tomography, X-Ray Computed; Zoledronic Acid | 2009 |
Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.
Topics: Animals; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Caspases; Cell Proliferation; Diphosphonates; Imidazoles; Lung Neoplasms; Male; Osteosarcoma; Rats; Rats, Inbred F344; Zoledronic Acid | 2010 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, External; Etidronic Acid; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation Mediators; Injections, Intraperitoneal; Injections, Subcutaneous; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Necrosis; Osteonecrosis; Osteosclerosis; Pamidronate; Pravastatin; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Technetium; Tibia; Time Factors; Zoledronic Acid | 2010 |
Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Zoledronic Acid | 2010 |
Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Giant Cell Tumor of Bone; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Osteoclasts; Treatment Outcome; Tumor Cells, Cultured; Young Adult; Zoledronic Acid | 2010 |
Bisphosphonates and atypical femoral fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Femoral Fractures; Hip Fractures; Humans; Imidazoles; Osteonecrosis; Risk Factors; Zoledronic Acid | 2010 |
Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma.
Topics: Acid Phosphatase; Animals; Bone Density Conservation Agents; Bone Resorption; Calcium; Carcinoma, Squamous Cell; Cats; Diphosphonates; Disease Models, Animal; Imidazoles; Isoenzymes; Luciferases; Male; Mice; Mice, Nude; Mouth Neoplasms; Osteoclasts; Osteolysis; Tartrate-Resistant Acid Phosphatase; Transplantation, Heterologous; X-Ray Microtomography; Zoledronic Acid | 2010 |
The effects of estrogen deficiency and bisphosphonate treatment on tissue mineralisation and stiffness in an ovine model of osteoporosis.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Estrogens; Female; Imidazoles; Models, Animal; Osteoporosis; Ovariectomy; Sheep; Zoledronic Acid | 2011 |
Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
Topics: Acid Phosphatase; Animals; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Cell Line, Tumor; Cell Movement; Diphosphonates; Diterpenes; Dose-Response Relationship, Drug; Gene Expression; I-kappa B Proteins; Imidazoles; Isoenzymes; Macrophages; Mice; Mice, Inbred Strains; NF-kappa B; NF-KappaB Inhibitor alpha; Osteoclasts; Phosphorylation; Protein Prenylation; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Stem Cells; Tartrate-Resistant Acid Phosphatase; Transcription, Genetic; Tumor Necrosis Factor-alpha; Up-Regulation; Zoledronic Acid | 2011 |
[Study on the effects of zoledronic-acid-loaded collagen membrane on bone metabolism cells].
Topics: Alkaline Phosphatase; Animals; Biocompatible Materials; Bone Density Conservation Agents; Bone Resorption; Cell Proliferation; Cells, Cultured; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Imidazoles; Membranes, Artificial; Osteoblasts; Osteoclasts; Osteogenesis; Rabbits; Zoledronic Acid | 2011 |
Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.
Topics: Animals; Blotting, Western; Bone Density Conservation Agents; Bone Marrow; Bone Resorption; Cell Differentiation; Cell Proliferation; Cells, Cultured; Chemokine CCL3; Diphosphonates; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Hematopoiesis; Humans; Imidazoles; Immunocompetence; Immunoenzyme Techniques; Leukemia, Myeloid; Male; Mice; Mice, Inbred C57BL; Osteoblasts; Osteoclasts; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spleen; Zoledronic Acid | 2012 |
In vitro generation of mature human osteoclasts.
Topics: Bone Resorption; Calcitonin; Diphosphonates; Humans; Imidazoles; Lipopolysaccharide Receptors; Microscopy, Phase-Contrast; Monocytes; Osteoclasts; Osteoprotegerin; Zoledronic Acid | 2011 |
Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Neurofibromatosis 1; Osteoclasts; Osteoporosis; Zoledronic Acid | 2012 |
Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Blotting, Western; Bone Resorption; Breast Neoplasms; Cell Proliferation; Diphosphonates; Female; Fibronectins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; MCF-7 Cells; Microarray Analysis; Real-Time Polymerase Chain Reaction; Thrombospondin 1; Transforming Growth Factor beta1; Up-Regulation; Zoledronic Acid | 2012 |
Calcium phosphate cement delivering zoledronate decreases bone turnover rate and restores bone architecture in ovariectomized rats.
Topics: Animals; Bone Cements; Bone Density Conservation Agents; Bone Resorption; Calcium Phosphates; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Wistar; Treatment Outcome; Zoledronic Acid | 2012 |
Dexrazoxane shows cytoprotective effects in zoledronic acid-treated human cells in vitro and in the rabbit tibia model in vivo.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Cell Culture Techniques; Cell Line; Cell Shape; Cell Survival; Collagen; Coloring Agents; Cytoprotection; Diphosphonates; Drug Carriers; Durapatite; Female; Fibroblasts; Fluoresceins; Fluorescent Dyes; Gingiva; Humans; Imidazoles; Models, Animal; Osteoblasts; Osteogenesis; Protective Agents; Rabbits; Razoxane; Tetrazolium Salts; Thiazoles; Tibia; Zoledronic Acid | 2012 |
Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report.
Topics: Adult; Aged; Bone Diseases; Bone Resorption; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteogenesis; Pain Measurement; Positron-Emission Tomography; Quality of Life; Retrospective Studies; Spine; Treatment Outcome; Zoledronic Acid | 2012 |
Marrow adiposity recovery after early zoledronic acid treatment of glucocorticoid-induced bone loss in rabbits assessed by magnetic resonance spectroscopy.
Topics: Absorptiometry, Photon; Adipocytes; Adiposity; Animals; Body Weight; Bone Density; Bone Marrow; Bone Marrow Cells; Bone Resorption; Diphosphonates; Female; Femur; Glucocorticoids; Imidazoles; Lipids; Magnetic Resonance Spectroscopy; Rabbits; Reproducibility of Results; Zoledronic Acid | 2013 |
Local treatment of a bone graft by soaking in zoledronic acid inhibits bone resorption and bone formation. A bone chamber study in rats.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Diffusion Chambers, Culture; Diphosphonates; Female; Imidazoles; Male; Osteogenesis; Random Allocation; Rats; Tibia; Titanium; Transplantation, Homologous; Treatment Outcome; Zoledronic Acid | 2012 |
Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
Topics: Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteolysis; Peptides; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2013 |
New drugs 2002, part III.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Antihypertensive Agents; Antirheumatic Agents; Bone Resorption; Bosentan; Cephalosporins; Darbepoetin alfa; Diphosphonates; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Erythropoietin; Heart Failure; Humans; Hypoglycemic Agents; Imidazoles; Indoles; Insulin; Insulin Aspart; Interleukin 1 Receptor Antagonist Protein; Natriuretic Agents; Natriuretic Peptide, Brain; Organophosphonates; Organophosphorus Compounds; Protein C; Recombinant Proteins; Serotonin Receptor Agonists; Sialoglycoproteins; Sulfonamides; Tenofovir; Tryptamines; Zoledronic Acid | 2002 |
Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
Topics: Animals; Bone and Bones; Bone Density; Bone Resorption; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Femur; Humans; Imidazoles; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Weight-Bearing; Zoledronic Acid | 2003 |
Zoledronate treatment in active Paget's disease.
Topics: Alkaline Phosphatase; Bone Resorption; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Osteitis Deformans; Zoledronic Acid | 2003 |
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects.
Topics: Bone Resorption; Breast Neoplasms; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Cyclooxygenase 2; Dinoprostone; Diphosphonates; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Imidazoles; Isoenzymes; Membrane Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Osteolysis; Prostaglandin-Endoperoxide Synthases; rhoA GTP-Binding Protein; Tumor Cells, Cultured; Zoledronic Acid | 2003 |
Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis.
Topics: Animals; Bone Marrow Cells; Bone Resorption; Cell Division; Cells, Cultured; Diphosphonates; Dose-Response Relationship, Drug; Imidazoles; Injections, Subcutaneous; Keratins; Male; Mice; Mice, Inbred C57BL; Minerals; Osteitis; Osteoclasts; Osteolysis; Parietal Bone; Periosteum; Prostheses and Implants; Skull; Zoledronic Acid | 2003 |
Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Resorption; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2003 |
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.
Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Female; Fever; Humans; Imidazoles; Interferon-gamma; Interleukin-6; Male; Middle Aged; Tumor Necrosis Factor-alpha; Zoledronic Acid | 2003 |
Severe hypocalcaemia after being given intravenous bisphosphonate.
Topics: Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Zoledronic Acid | 2004 |
Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid.
Topics: Animals; Biomarkers; Bone Density; Bone Resorption; Compressive Strength; Diphosphonates; Dose-Response Relationship, Drug; Estrogens; Female; Imidazoles; Lumbar Vertebrae; Osteocalcin; Ovariectomy; Rats; Rats, Sprague-Dawley; Time Factors; Tomography; Zoledronic Acid | 2004 |
Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
Topics: Bone Resorption; Breast Neoplasms; Diphosphonates; Drug Resistance; Female; Humans; Hypercalcemia; Imidazoles; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Pamidronate; Quality of Life; Recurrence; Zoledronic Acid | 2004 |
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.
Topics: Animals; Antibodies, Monoclonal; Arthritis; Arthrography; Bone and Bones; Bone Density; Bone Resorption; Calcitonin; Cartilage, Articular; Diphosphonates; Hindlimb; Humans; Imidazoles; Infliximab; Joints; Mice; Mice, Transgenic; Osteoclasts; Osteogenesis; Tomography, X-Ray Computed; Tumor Necrosis Factor-alpha; Zoledronic Acid | 2004 |
Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis.
Topics: Animals; Arthritis, Experimental; Arthrography; Biomarkers; Bone Resorption; Diphosphonates; Female; Hindlimb; Imidazoles; Joints; Osteoclasts; Rats; Rats, Inbred Strains; Severity of Illness Index; Synovial Membrane; Synovitis; Tomography, X-Ray Computed; Zoledronic Acid | 2004 |
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Topics: Bone Neoplasms; Bone Resorption; Controlled Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2004 |
Short-term safety assessment in the use of intravenous zoledronic acid in children.
Topics: Adolescent; Bone Resorption; Calcium; Child; Child, Preschool; Creatinine; Diphosphonates; Female; Fever; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Male; Nausea; Pain; Phosphorus; Retrospective Studies; Time Factors; Urea; Vomiting; Zoledronic Acid | 2004 |
Novel biomaterials for bisphosphonate delivery.
Topics: Animals; Biocompatible Materials; Bone Resorption; Calcium Phosphates; Cells, Cultured; Diphosphonates; Drug Carriers; Drug Implants; Imidazoles; Materials Testing; Osteoblasts; Rabbits; Surface Properties; Zoledronic Acid | 2005 |
Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Pain; Prostatic Neoplasms; Zoledronic Acid | 2005 |
Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Cations, Divalent; Diphosphonates; Imidazoles; Isoenzymes; Magnesium; Osteoblasts; Osteosarcoma; Pamidronate; Rats; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2005 |
Ask us: Some drugs affect tooth movement.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoclasts; Tooth Movement Techniques; Zoledronic Acid | 2005 |
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Neoplasms; Bone Resorption; Cohort Studies; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Osteogenesis; Predictive Value of Tests; Prognosis; Zoledronic Acid | 2005 |
[A comparison of the antiresorptive effects of bisphosphonates and statins on polyethylene particle-induced osteolysis].
Topics: Animals; Bone Resorption; Diphosphonates; Female; Foreign-Body Reaction; Imidazoles; Male; Mice; Mice, Inbred C57BL; Osteolysis; Particle Size; Polyethylenes; Simvastatin; Skull; Treatment Outcome; Zoledronic Acid | 2005 |
Zoledronic acid improves femoral head sphericity in a rat model of perthes disease.
Topics: Animals; Bone Resorption; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Femur Head; Imidazoles; Legg-Calve-Perthes Disease; Rats; Rats, Inbred SHR; Zoledronic Acid | 2005 |
Treatment of Paget's disease--taming the wild osteoclast.
Topics: Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Resorption; Diphosphonates; Glycoproteins; Humans; Imidazoles; Osteitis Deformans; Osteoclasts; Osteoprotegerin; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Zoledronic Acid | 2005 |
Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cartilage; Child; Child, Preschool; Diaphyses; Diphosphonates; Humans; Imidazoles; Osteogenesis Imperfecta; Osteoporosis; Rabbits; Tibia; Time Factors; Zoledronic Acid | 2005 |
Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Mandibular Diseases; Maxillary Diseases; Multiple Myeloma; Osteomyelitis; Osteonecrosis; Zoledronic Acid | 2005 |
[Osteoporosis and anti-androgenic therapy in case of prostate cancer].
Topics: Androgen Antagonists; Bone Resorption; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Osteoporosis; Prognosis; Prostatic Neoplasms; Risk Factors; Survival; Zoledronic Acid | 2005 |
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Topics: Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Magnesium Deficiency; Urogenital Neoplasms; Zoledronic Acid | 2006 |
Systemic zoledronate precoating of a bone graft reduces bone resorption during remodeling.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Bone Transplantation; Diphosphonates; Female; Graft Rejection; Imidazoles; Male; Rats; Rats, Sprague-Dawley; Zoledronic Acid | 2006 |
Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
Topics: Adult; Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Peptides; Time Factors; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2006 |
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Magnesium Deficiency; Male; Prostatic Neoplasms; Urogenital Neoplasms; Zoledronic Acid | 2006 |
Quantitative and reliable in vitro method combining scanning electron microscopy and image analysis for the screening of osteotropic modulators.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Carrier Proteins; Cells, Cultured; Diphosphonates; Image Processing, Computer-Assisted; Imidazoles; Membrane Glycoproteins; Microscopy, Electron, Scanning; Microscopy, Fluorescence; Osteoclasts; Rabbits; RANK Ligand; Time Factors; Zoledronic Acid | 2006 |
Systemic zoledronate treatment both prevents resorption of allograft bone and increases the retention of new formed bone during revascularization and remodelling. A bone chamber study in rats.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Regeneration; Bone Remodeling; Bone Resorption; Bone Transplantation; Diffusion Chambers, Culture; Diphosphonates; Female; Graft Survival; Imidazoles; In Vitro Techniques; Male; Osteoclasts; Rats; Rats, Sprague-Dawley; Tibia; Zoledronic Acid | 2006 |
Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Transplantation, Homologous; Zoledronic Acid | 2006 |
Case studies in metastatic bone disease: understanding the unique nature of bone loss due to malignancy.
Topics: Aftercare; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Early Diagnosis; Humans; Imidazoles; Nurse's Role; Nursing Assessment; Oncology Nursing; Pamidronate; Patient Care Planning; Patient Education as Topic; Quality of Life; Risk Assessment; Vitamin D; Zoledronic Acid | 2006 |
The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro.
Topics: Antigens, Differentiation; Bone Density Conservation Agents; Bone Resorption; Bone Substitutes; Cell Differentiation; Cells, Cultured; Coated Materials, Biocompatible; Diphosphonates; Humans; Imidazoles; Materials Testing; Osteoblasts; Osteoclasts; Polyesters; Zoledronic Acid | 2007 |
Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Infectious; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Female; Imidazoles; Interleukin-6; Mice; Osteoclasts; Osteoporosis; Staphylococcal Infections; Staphylococcus aureus; Zoledronic Acid | 2007 |
Effects of bisphosphonate treatment on bone repair under immunosuppression using cyclosporine A in adult rats.
Topics: Animals; Biomarkers; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Bone Transplantation; Cyclosporine; Diphosphonates; Drug Interactions; Fractures, Bone; Graft Survival; Imidazoles; Immunosuppressive Agents; Male; Osteogenesis; Osteoporosis; Rats; Rats, Inbred Lew; Tibia; Zoledronic Acid | 2007 |
Bone turnover 18 months after a single intravenous dose of zoledronic acid.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Prospective Studies; Risk Factors; Treatment Outcome; Zoledronic Acid | 2007 |
Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.
Topics: Animals; Bone Resorption; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Immunologic; Female; Hydroxycholecalciferols; Hypercalcemia; Imidazoles; Immunity, Innate; Immunoglobulin G; Influenza A Virus, H3N2 Subtype; Longitudinal Studies; Male; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Recombinant Fusion Proteins; Zoledronic Acid | 2007 |
Re: 'A single zoleledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density' by Saag et al.
Topics: Administration, Oral; Alendronate; Biomarkers; Bone Density; Bone Resorption; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Time Factors; Zoledronic Acid | 2007 |
By the way, doctor. Should I take an intravenous drug for osteoporosis?
Topics: Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Zoledronic Acid | 2007 |
Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cell Division; Diphosphonates; Imidazoles; Kinetics; Macrophages; Mice; Mice, Knockout; Neoplasm Metastasis; Osteoclasts; Receptors, CXCR4; Zoledronic Acid | 2007 |
Zoledronic acid-induced IPP/ApppI production in vivo.
Topics: Adenosine Triphosphate; Animals; Bone Density Conservation Agents; Bone Marrow Cells; Bone Resorption; Cells, Cultured; Diphosphonates; Geranyltranstransferase; Hemiterpenes; Imidazoles; Macrophages, Peritoneal; Mevalonic Acid; Mice; Organophosphorus Compounds; Time Factors; Zoledronic Acid | 2007 |
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Zoledronic Acid | 2007 |
Development of a low-dose anti-resorptive drug regimen reveals synergistic suppression of bone formation when coupled with disuse.
Topics: Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Resorption; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Femur; Hindlimb Suspension; Imidazoles; Mice; Mice, Inbred C57BL; Osteoblasts; Osteogenesis; Osteoporosis; Osteoprotegerin; Space Flight; Tomography, X-Ray Computed; Weightlessness Countermeasures; Zoledronic Acid | 2008 |
Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography.
Topics: Animals; Bone Demineralization, Pathologic; Bone Density Conservation Agents; Bone Resorption; Compressive Strength; Diphosphonates; Disease Models, Animal; Elasticity; Female; Imidazoles; Osteoporosis; Ovariectomy; Rats; Rats, Wistar; Stress, Mechanical; Tibia; Tomography, X-Ray Computed; Zoledronic Acid | 2008 |
Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
Topics: Acid Phosphatase; Alkaline Phosphatase; Animals; Biomechanical Phenomena; Body Weight; Bone Density; Bone Remodeling; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Endometrium; Estradiol; Female; Femur; Genistein; Genotype; Imidazoles; Isoenzymes; Liver; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Knockout; Osteoprotegerin; RANK Ligand; Tartrate-Resistant Acid Phosphatase; Tibia; Uterus; Zoledronic Acid | 2008 |
Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Case-Control Studies; Collagen Type I; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Zoledronic Acid | 2008 |
Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro.
Topics: Animals; Apatites; Biocompatible Materials; Bone Density Conservation Agents; Bone Resorption; Calcium Phosphates; Cells, Cultured; Diphosphonates; Drug Carriers; Drug Delivery Systems; Imidazoles; Materials Testing; Osteoblasts; Osteoclasts; Rabbits; Zoledronic Acid | 2009 |
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Peptides; Retrospective Studies; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2008 |
Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice.
Topics: Acid Phosphatase; Alkaline Phosphatase; Alveolar Bone Loss; Animals; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Imidazoles; Isoenzymes; Mandible; Mice; Mice, Inbred C57BL; Mice, Knockout; Osteoprotegerin; Random Allocation; Tartrate-Resistant Acid Phosphatase; Tibia; Zoledronic Acid | 2009 |
Effects of two novel bisphosphonates on bone cells in vitro.
Topics: Animals; Bone and Bones; Bone Resorption; Breast Neoplasms; Cell Count; Cells, Cultured; Culture Media, Conditioned; Diphosphonates; DNA; Dose-Response Relationship, Drug; Edetic Acid; Female; Humans; Imidazoles; Osteoblasts; Osteoclasts; Pamidronate; Rats; Tumor Cells, Cultured; Zoledronic Acid | 1994 |
Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.
Topics: Animals; Bone and Bones; Bone Density; Bone Resorption; Calcitriol; Calcium; Diphosphonates; Drug Evaluation, Preclinical; Hypercalcemia; Imidazoles; Interleukin-1; Male; Mice; Parathyroid Hormone; Parathyroid Hormone-Related Protein; Parathyroidectomy; Peptide Fragments; Proteins; Rats; Thyroidectomy; Zoledronic Acid | 1994 |
Zoledronate: the preclinical pharmacology.
Topics: Animals; Bone Resorption; Cholecalciferol; Depression, Chemical; Diphosphonates; Disease Models, Animal; Female; Hypercalcemia; Imidazoles; Ovariectomy; Pamidronate; Parathyroidectomy; Rats; Thyroidectomy; Zoledronic Acid | 1996 |
Zoledronate in the treatment of osteolytic bone metastases.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 1996 |
Research on bone metastases quickens its pace.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Neoplasm Proteins; Palliative Care; Parathyroid Hormone-Related Protein; Proteins; Zoledronic Acid | 1997 |
Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys.
Topics: Absorptiometry, Photon; Analysis of Variance; Animals; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Female; Imidazoles; Macaca mulatta; Ovariectomy; Regression Analysis; Zoledronic Acid | 1998 |
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Resorption; Cell Division; Cell Survival; Diphosphonates; Humans; Imidazoles; Interleukin-1; Interleukin-6; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Multiple Myeloma; Pamidronate; Tumor Cells, Cultured; Zoledronic Acid | 1999 |
Zolendronate (zometa).
Topics: Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Fees, Pharmaceutical; Half-Life; Humans; Imidazoles; Zoledronic Acid | 2001 |